Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2a dose-finding study of BMS-986507 combinations in advanced solid tumors
2024-514947-27-00Phase 2Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 8
01
Overview
Phase 2, open-label trial of izalontamab brengitecan in Nonhematologic neoplasms (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Number of participants with adverse events, Number of participants with serious adverse events and 4 more. Planned start Jun 2025; status: authorised.
02
Drugs
izalontamab brengitecan
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2024-514947-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514947-27-00.